Seekyo Therapeutics reported preclinical progress on a Tumor Activated Therapy (SKY01) that leverages albumin binding and tumor‑microenvironment enzyme activation to release a cytotoxic payload selectively in solid tumors. The approach aims to affect heterogeneous tumor cells by targeting functional proteins and extracellular enzymes rather than single surface markers. Separately, Berkeley researchers improved Cas9 nuclear delivery by inserting additional nuclear localization signals into internal loops, enhancing gene‑editing efficiency in human T cells without compromising protein expression. The modification could boost ex vivo cell‑therapy manufacturing yields and in vivo editing efficacy. Both developments represent engineering advances—one in targeted payload activation and one in delivery of gene‑editing effectors—that could influence next‑generation oncology therapeutics if subsequent preclinical and clinical validation support safety and activity.